Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Conceptual business illustration of upcoming business problem metaphor with falling domino and businessman silhouette. Minimalistic vector eps 10 illustration

Weight loss

Lilly Cuts Mid-Stage Obesity Study of Muscle-Sparing Antibody

The decision to stop the Phase IIb study was driven by “strategic business reasons,” according to a federal clinical trials database.

September 25, 2025

2 min read

Tristan Manalac

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).

FDA

FDA Details Thinking for Streamlining Development of Cell, Gene, Regenerative Therapies

Three draft recommendation documents published on Wednesday are intended to guide drug sponsors and accelerate the development of cell and gene therapies.

September 25, 2025

2 min read

Tristan Manalac

Wooden blocks with arrow and error icon. Delays and disruptions, stop the process, critical error concept

Rare diseases

Harmony Fails Pivotal Fragile X Syndrome Trial, Blames High Placebo Response

While Harmony management has not disclosed future plans for ZYN002, Jefferies analysts expect the asset to be shelved.

September 25, 2025

1 min read

Tristan Manalac

IN PARTNERSHIP WITH PTP

Webinar: Data Lakes & FAIR Principles: Making Scientific Data Accessible and Actionable

In this discussion, our guests explore how modern data lake architectures, built on AWS, can help your organization adopt FAIR data principles—Findable, Accessible, Interoperable, and Reusable—to unlock the full potential of your scientific data.

September 24, 2025

1 min read

BioSpace Insights

Pop collage poster of person worker use gadget on pastel background with line button arrows up.

Job Trends

Talent Acquisition Leaders Reframe Recruiting, Focus On Internal Mobility

Talent acquisition leaders at leading pharma and biotech organizations are leveraging technologies, including automation, to develop internal talent marketplaces and systems that support upskilling and reskilling their workforce. BioSpace spoke to leaders at Pfizer and Bayer about their evolving approach to resourcing.

September 24, 2025

3 min read

Chantal Dresner

Accumulated problems, contradictions. Dead end, we need to go back. You cannot continue further. Complete impossibility to continue. Rejection of an idea. Hard sanctions. Fatal error.

Rare diseases

Acadia Scraps Prader-Willi Drug After Late-Stage Failure

Acadia Pharmaceuticals was testing the drug, an intranasal formulation of the oxytocin analogue carbetocin, for its potential to ease hyperphagia in the rare neurological condition.

September 24, 2025

1 min read

Dan Samorodnitsky

Pictured: Blue and white Sanofi sign on building/R

Venture capital

Sanofi Fattens Venture Unit With $625M Infusion for Rare Disease, Neuro Innovation

Sanofi Ventures, which now has $1.4 billion in total assets, will focus its investment efforts on early players working in immunology, rare diseases, neurology and vaccines.

September 24, 2025

2 min read

Tristan Manalac

Pictured: uniQure headquarters in Amsterdam

Huntington’s disease

UniQure ‘Exceeds Expectations’ in Much-Anticipated 3-Year Huntington’s Readout

If approved, uniQure’s gene therapy AMT-130—which slowed disease progression by 75%—would be the first genetic treatment for Huntington’s disease. A BLA submission is planned for the first quarter of 2026.

September 24, 2025

2 min read

Heather McKenzie